Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, announced results from two Phase 1/2 clinical trials evaluating ...

US oncology biotech Revolution Medicines has reported early Phase I/II data for zoldonrasib-based combinations in RAS G12D-mutant metastatic pancreatic ductal adenocarcinoma (PDAC), supporting two ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced ...

Dr. Erica Mayer of Dana-Farber highlights new data on chemotherapy-free HER2+ treatment, ctDNA monitoring and oral SERDs at ESMO Breast 2026. In the wake of the 2026 ESMO Breast Cancer conference, ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...

Globally, pancreatic cancer constitutes the seventh leading cause of cancer-related mortality and the second leading cause in the US — it is expected to retain these positions through at least 2030. 3 ...

At the European Society for Medical Oncology (ESMO) Annual Meeting 2025, held recently in Berlin, experts presented an early evaluation of the European Health Technology Assessment (HTA) Regulation, ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...

From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the ...

VCN-01 combined with standard therapy improved overall survival and progression-free survival in metastatic pancreatic ductal adenocarcinoma patients. The VIRAGE trial showed a 56% reduction in death ...